News
News about Imperial technology development and commercial deals
Filter by theme
Accelerated development of a potential treatment for cystic fibrosis
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Read more
Natural Killer – licensing a cell therapy
Imperial has licensed iNKT cell technology based on research by Prof. Tassos Karadimitris to SUDA Pharmaceuticals. Read more
Imperial partner Apollo receives £100m to boost medical research at leading unis
Imperial will benefit from continued support for translational biomedical research under a unique technology transfer model. Read more
Sign up for updates
Sign up for monthly technology alerts via email, and find other ways to connect with us.